News from essa pharma inc A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 06, 2023, 07:00 ET ESSA Pharma Appoints Lauren Merendino to its Board of Directors

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 6, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

Jun 01, 2023, 07:00 ET ESSA Pharma to Present at 2023 Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 1, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

May 11, 2023, 07:00 ET ESSA Pharma to Present at JMP Securities Life Sciences Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, May 11, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

May 09, 2023, 07:00 ET ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2023

Entered into clinical trial support agreement with Janssen to supply Erleada® (apalutamide) and Zytiga® (abiraterone acetate) for an ESSA-sponsored...

Apr 18, 2023, 07:00 ET ESSA Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, April 18, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

Apr 12, 2023, 07:00 ET ESSA Pharma Announces Clinical Trial Support Agreement with Janssen to Evaluate EPI-7386 Combinations in Patients with Prostate Cancer

SOUTH SAN FRANCISCO, Calif., and VANCOUVER, Canada, April 12, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

Mar 08, 2023, 07:00 ET ESSA Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 8, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

Feb 13, 2023, 17:00 ET ESSA Pharma Announces Presentations at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU)

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 13, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

Feb 07, 2023, 07:00 ET ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2022

Completion of Phase 1 EPI-7386 combination study with enzalutamide expected in 1H2023 followed by initiation of the randomized Phase 2 study Phase 1b ...

Feb 02, 2023, 16:01 ET ESSA Pharma to Participate in the Guggenheim Healthcare Talks 5th Annual Oncology Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Feb. 2, 2023 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

Dec 13, 2022, 07:00 ET ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2022

SOUTH SAN FRANCISCO, CALIFORNIA and VANCOUVER, CANADA, Dec. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

Nov 10, 2022, 07:00 ET ESSA Pharma to Participate in Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Nov. 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

Oct 31, 2022, 07:00 ET ESSA Provides an Update on its Clinical Collaboration with Janssen

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Oct. 31, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

Oct 26, 2022, 16:01 ET ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Oct. 26, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

Oct 26, 2022, 07:00 ET Updated Results from the Phase 1/2 Study of ESSA's Lead Candidate EPI-7386 in Combination with Enzalutamide Highlighted at the 29th Annual Prostate Cancer Foundation Scientific Retreat

EPI-7386 in combination with enzalutamide was safe and well-tolerated at the doses tested with clinically relevant drug exposures and deep and...

Sep 13, 2022, 07:00 ET ESSA Pharma Appoints Philip Kantoff to its Board of Directors

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Sept. 13, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

Aug 04, 2022, 07:00 ET ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Third Quarter Ended June 30, 2022

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, Aug. 4, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

Jun 27, 2022, 16:01 ET ESSA Pharma Presents Clinical Update on EPI-7386 Monotherapy and Combination Therapy Clinical Development

EPI-7386 was safe and well-tolerated at all dose levels and schedules tested with plasma target concentrations achieved and clinically important...

Jun 02, 2022, 07:00 ET ESSA Pharma to Present at 2022 Jefferies Healthcare Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, June 2, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

May 10, 2022, 07:00 ET ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Second Quarter Ended March 31, 2022

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, Canada, May 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

Apr 26, 2022, 16:30 ET ESSA Pharma to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, April 26, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

Apr 08, 2022, 13:00 ET ESSA Pharma Announces the Presentation of Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders

Orally bioavailable ANITAC™ degraders can eliminate full length, mutant and splice variant forms of AR that are expressed in castration-resistant...

Mar 10, 2022, 16:05 ET ESSA Pharma to Present at Oppenheimer Annual Healthcare Conference

South San Francisco, California and Vancouver, Canada, March 10, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA", or the "Company") (NASDAQ: EPIX), a...

Mar 09, 2022, 23:34 ET ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

SOUTH SAN FRANCISCO, California and VANCOUVER, Canada, March 9, 2022 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ: EPIX), a...

Mar 08, 2022, 16:30 ET ESSA Pharma to Present Preclinical Data for its First Generation of Androgen Receptor N-Terminal Domain Degraders at the 2022 American Association for Cancer Research (AACR) Annual Meeting

First presentation of preclinical data for ESSA's androgen receptor (AR) N-terminal domain degraders ANITen bAsed Chimera (ANITAC™) degraders degrade ...